Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kyowa Kirin acquires Asian rights to Reata's lead drug

This article was originally published in Scrip

Executive Summary

Reata Pharmaceuticals has licensed its lead development project bardoxolone methyl (RTA 402) to Kyowa Hakko Kirin for development and commercialisation in Japan and other Asian markets.

You may also be interested in...



Outlook For Reata's Bardoxolone Improves With Phase II Updates

Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.

Takeda Sees Mainstays Tiding It Over Upcoming Expiries

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Topics

Related Companies

UsernamePublicRestriction

Register

SC006340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel